NCT01493427View on ClinicalTrials.gov

Efficacy of Changing to TRAVATAN® From Prior Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
Open-Angle GlaucomaOcular Hypertension
Interventions
DRUG

Travoprost 0.004%

Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT01493427 - Efficacy of Changing to TRAVATAN® From Prior Therapy | Biotech Hunter | Biotech Hunter